Novo Nordisk Aktie
WKN DE: A3EU6F / ISIN: DK0062498333
19.11.2024 14:33:30
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | David Moore | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President, head of Corporate Development | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | ADRs | |||
Identification code | NVO | ||||
b) | Nature of the transaction | Purchase of ADRs | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 709.25 | 2,500 ADRs | ||||
d) | Aggregated information
| 2,500 ADRs DKK 1,773,118.70 | |||
e) | Date of the transaction | 2024-11-18 | |||
f) | Place of the transaction | New York Stock Exchange |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media: | |
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
Investors: | |
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com | David Heiberg Landsted
+45 3077 6915 dhel@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com | Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Company Announcement No 90 / 2024
Attachment


Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novo Nordiskmehr Nachrichten
28.03.25 |
Börse Europa: STOXX 50 am Freitagnachmittag leichter (finanzen.at) | |
28.03.25 |
Stoxx Europe 50-Titel Novo Nordisk-Aktie: Über diese Dividendenzahlung können sich Novo Nordisk-Aktionäre freuen (finanzen.at) | |
28.03.25 |
Verluste in Europa: STOXX 50 zeigt sich am Freitagmittag schwächer (finanzen.at) | |
28.03.25 |
Schwacher Handel in Europa: STOXX 50 zum Start leichter (finanzen.at) | |
27.03.25 |
Handel in Europa: STOXX 50 verbucht zum Handelsende Abschläge (finanzen.at) | |
27.03.25 |
Handel in Europa: STOXX 50 gibt nach (finanzen.at) | |
27.03.25 |
Schwacher Wochentag in Europa: STOXX 50 fällt am Mittag zurück (finanzen.at) | |
27.03.25 |
Anleger in Europa halten sich zurück: STOXX 50 schwächelt zum Handelsstart (finanzen.at) |
Analysen zu Novo Nordiskmehr Analysen
28.03.25 | Novo Nordisk Buy | UBS AG | |
28.03.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
28.03.25 | Novo Nordisk Buy | UBS AG | |
24.03.25 | Novo Nordisk Buy | Deutsche Bank AG | |
24.03.25 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) |
Aktien in diesem Artikel
Novo Nordisk | 64,08 | -1,99% |
|